SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Superfruits AI is redefining the Web3 landscape with an ecosystem of fruit-themed AI agents offering specialized insights and services, ranging from blockchain security to market sentiment analysis. Building on this vibrant foundation, we're introducing groundbreaking features like a proprietary Web3-trained AI model, an interactive Virtual Research Room, and the innovative concept of "Juices." These "Juices" empower high token holders to mix and match agents' capabilities, creating custom virtual rooms where agents collaborate on tailored analyses for portfolios or projects. By blending cutting-edge AI with gamified user experiences, Superfruits AI positions itself as a pioneer in Web3 analytics, offering unique tools that not only secure but also enrich the decentralized journey for every user.

SuperFruits AI

SuperFruits AI ($SUPAI) is gaining attention as traders discuss potential breakouts and strong chart structure, with many highlighting the convergence of AI technology and market momentum. The community emphasizes disciplined trading and watching for confirmation signals amid increasing volume and controlled price action. Some observers note $SUPAI's resilience and potential divergence from broader crypto market trends.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin's price volatility has traders on edge, with liquidations and potential market manipulation being hot topics. Community sentiment is mixed, with some anticipating a rally while others foresee a significant pullback, leading to debates about long-term holding versus short-term trading strategies. The broader discussion includes the impact of institutional investors and potential regulatory changes on Bitcoin's future.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is trending as investors weigh the potential impact of Bitcoin's price movements and upcoming dividend payouts. Community discussions revolve around strategies like selling covered calls and predictions for the dividend amount, alongside debates on BITO's long-term value compared to holding Bitcoin directly or similar ETFs. Broader market sentiment and potential regulatory changes in the crypto space also contribute to the ongoing conversation.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum's price action is sparking intense debate, with discussions around potential bear traps and bullish accumulation patterns. Community members are weighing in on technical analysis, with some anticipating a significant rally towards year-end while others express concerns about weakness and potential manipulation. Amidst the volatility, broader narratives around tokenization and institutional involvement in ETH are also circulating.

XDC Network is an enterprise-ready hybrid Blockchain technology company optimized for international trade and finance. The XDC Network is powered by the native coin called XDC. The XDC protocol is architected to support smart contracts, 2000TPS, 2seconds transaction time, KYC to Masternodes (Validator Nodes). The XDC Chain (XinFin Digital Contract) uses XinFin Delegated Proof of Stake (XDPoS), with the intending to create a ‘highly-scalable, secure, permission, and commercial grade’ blockchain network. XinFin mainnet token XDC and also creates an opportunity to utilize the XinFin’s real-world use-cases such as TradeFinex.org, helps small and medium businesses or institutions originate their own financial requirements in a digital, fully structured manner so that they can distribute it to the bank or non-bank funders themselves using a common distribution standard.

XinFin Network

XDC is trending as the community discusses its potential in real-world asset tokenization and trade finance, particularly its integration with established financial networks. Despite recent price stagnation, some investors are accumulating XDC, anticipating significant growth and a potential breakout, drawing comparisons to other ISO 20022 compliant cryptos. Conversations also highlight speculation around potential ETF listings and increased tradability on major exchanges as future catalysts.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending due to renewed interest in its role in AI infrastructure, highlighted by key partnerships and increasing AI-related orders. The community is discussing the potential for a resurgence reminiscent of past tech giants, with some analysts setting optimistic price targets. Despite some debate over valuation and competition, many see Cisco as undervalued, poised for growth in the evolving tech landscape.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending alongside Bitcoin's price movements and recent positive momentum, with potential rate cuts and institutional interest fueling bullish sentiment. The community is actively discussing price targets and trading strategies, particularly around options, while also debating whether Bitcoin can sustain recent gains or if a significant pullback is imminent. Competing narratives of Bitcoin as "digital gold" versus a speculative asset continue to drive conversation.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is trending as the community discusses its potential for an earnings surprise and the possibility of a buyout, fueled by strong sales and a low PE ratio. Community members are closely watching for news that could drive the stock higher, including potential partnerships and FDA approvals. Some traders are debating whether the stock is overbought, while others point to its strong fundamentals and growth potential.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Shares of AUPH are trending downwards amidst community concerns over recent commentary from an FDA official regarding the company's drug LUPKYNIS. The community is actively discussing potential conflicts of interest, the lack of an official response from the company, and what impact it will have on future growth and the development of AUR200. Some investors are calling for legal action and emphasizing the need for strong leadership to address the situation and defend shareholder value.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending downwards amid broader concerns about Ethereum's price action and its potential impact on the company's profitability. Community chatter includes accusations of fraud and a pump and dump scheme, with some questioning the CEO's strategy and the timing of share dilution. Some traders express concerns over crypto market volatility and comparisons to other treasury stocks.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors who lost money on Baxter International, Inc.(BAX) should contact Levi & Korsinsky about pending Class Action - BAX

Investors who lost money on Baxter International, Inc.(BAX) should contact Levi & Korsinsky about pending Class Action - BAX Investors who lost money on Baxter International, Inc.(BAX) should contact...

<ul class="summary-bullets"><li>Baxter’s Q3 profit rose 41% year-over-year, but gross margin plunged 430 basis points to 39.4% amid higher manufacturing costs and weak IV solution demand.</li><li>The company cut its 2025 EPS and sales forecasts and announced a dividend reduction starting January 2026 to accelerate debt repayment.</li><li>Shipment delays for its Novum infusion pump and continued fluid conservation in U.S. hospitals are expected to weigh on near-term performance.</li></ul>Shares of Baxter International Inc. fell sharply on Thursday, logging their worst session in three months, after the medical products company’s upbeat profit performance was outweighed by weaker margins, reduced guidance, and lingering operational challenges.The stock plunged 14.5% to $19.16 on Thursday, before recovering 1.6% in after-hours trading.<h2 class="st-heading-2">Margins Sink Despite Strong Earnings</h2>For the third quarter (Q3), Baxter reported $2.8 billion in sales, up 5% year-over-year, and an adjusted EPS of $0.69, a 41% increase from last year, marking its highest quarterly profit since 2022.However, the improvement was driven primarily by one-time benefits including temporary service agreement (TSA) income and cost discipline, while underlying operational momentum remained sluggish.The company’s gross margin plunged 430 basis points to 39.4%, hit by product mix shifts, lower IV solution volumes, and higher manufacturing costs. Operating margin also narrowed, forcing Baxter to cut full-year guidance for both revenue and earnings.<h2 class="st-heading-2">Infusion Pump Delays And Weak Hospital Demand&nbsp;</h2>Sales from Infusion Therapies and Technologies (ITT) fell 4% operationally, due to ongoing shipment holds for the Novum IQ Large Volume Pump (LVP),&nbsp; an issue the company now expects to extend beyond 2025 because of unresolved flow rate problems.Meanwhile, demand for IV solutions in U.S. hospitals remained soft as health systems continued fluid-conservation measures following Hurricane Helene, delaying recovery in one of Baxter’s core markets.The company also cited tariff costs of about $40 million this year and supply chain inefficiencies from lower production volumes as additional drags on profitability.<h2 class="st-heading-2">Dividend Cut And Guidance Reduction&nbsp;</h2>Baxter said it would slash its quarterly dividend to $0.01 per share starting January 2026, freeing up over $300 million in annual cash flow to pay down debt. It aims to bring net leverage down to 3x by the end of 2026, before resuming more aggressive capital deployment.The company lowered its 2025 adjusted EPS outlook to $2.35–$2.40 (from $2.42–$2.52 previously) and trimmed its full-year sales growth target to 4%–5% reported, or just 1%–2% operationally.Fourth-quarter guidance also disappointed, with EPS projected between $0.52 and $0.57, reflecting continued volume softness and margin pressure.<h2 class="st-heading-2">New CEO Faces Challenge Of Stabilizing Operations</h2>Newly appointed CEO Andrew Hider said the focus is on stabilizing the business, strengthening the balance sheet, and embedding a “continuous improvement” culture through a new internal program called Baxter GPS (Growth and Performance System).Hider acknowledged the near-term headwinds but maintained that the company’s diversified hospital product portfolio and cash flow discipline position it well for recovery.<h2 class="st-heading-2">Baxter Draws Wave Of Optimism On Stocktwits</h2>On Stocktwits, retail sentiment for Baxter was ‘extremely bullish’ amid a 2,100% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:970/147;" src="https://news.stocktwits-cdn.com/bax_ss_jpg_2c6bbe4b2a.webp" alt="bax ss.jpg" width="970" height="147"><figcaption>BAX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>One user said they had started a position below $20 and saw it as an easy long-term hold.<stembedurl>https://stocktwits.com/thalkdoi/message/634381485</stembedurl>Another user argued the stock was undervalued given Baxter’s long history and dominant role in U.S. healthcare, suggesting it remained a strong candidate for long-term gains.<stembedurl>https://stocktwits.com/SpaceForceOne/message/634337975</stembedurl><a href="https://stocktwits.com/symbol/BAX">Baxter’s stock</a> has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Baxter International logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Baxter Stock Logs Worst Day In 3 Months On Margin Pain And Weak Guidance — Retail Sees Long-Term Buy Opportunity

The company cut its 2025 EPS and sales forecasts and announced a dividend reduction starting January 2026 to accelerate debt repayment.

Equity

Deadline Alert: Baxter International, Inc. (BAX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...

Here's What Key Metrics Tell Us About Baxter (BAX) Q3 Earnings

While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BAX Stock Falls Following Q3 Earnings Beat & Sales Miss, '25 EPS View Down

Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.

Investors in Baxter International, Inc. Should Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - BAX

Investors in Baxter International, Inc. Should Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - BAX Investors in Baxter International, Inc. Should Contact The Gross Law...

Baxter International (BAX) Beats Q3 Earnings Estimates

Baxter (BAX) delivered earnings and revenue surprises of +15.00% and -1.32%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Baxter Reports Third-Quarter 2025 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. I joined Baxter because its a global healthcare leader an iconic brand with an...

BAX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

BAX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit BAX INVESTOR NOTICE...

Deadline Approaching: Baxter International, Inc. (BAX) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith

Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Baxter...

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Baxter International Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.55	--	--	N/A
Q3 '25	$0.60	$0.69	15.40%	BEAT
Q2 '25	$0.61	$0.59	-3.31%	MISSED
Q1 '25	$0.48	$0.55	13.75%	BEAT
Q4 '24	$0.52	$0.58	11.91%	BEAT

BAX
Baxter International Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest BAX News

BAXBaxter International Inc.